(Q37939271)

25 August 2017

1 reference

title

Direct renin inhibition: from pharmacological innovation to novel therapeutic opportunities (English)

1 reference

25 August 2017

1 reference

1

1 reference

25 August 2017

Roberto Pontremoli

2

1 reference

25 August 2017

Claudio Borghi

series ordinal

3

1 reference

25 August 2017

publication date

1 September 2011

1 reference

High Blood Pressure & Cardiovascular Prevention

25 August 2017

published in

1 reference

25 August 2017

volume

18

1 reference

25 August 2017

issue

3

1 reference

25 August 2017

page(s)

93-105

1 reference

https://scigraph.springernature.com/pub.10.2165/11593540-000000000-00000

25 August 2017

exact match

0 references

cites work

Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular disease?

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Angiotensin-II receptor blockers: benefits beyond blood pressure reduction?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Aliskiren: a review of its use in the management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Aliskiren, the future of renin-angiotensin system blockade?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Direct renin inhibition with aliskiren in hypertension and target organ damage

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Renin inhibition with aliskiren: where are we now, and where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Essential hypertension: renin and aldosterone, heart attack and stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Cardio-renal protection with aliskiren, a direct renin inhibitor, in the ASPIRE HIGHER program

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11593540-000000000-00000

Cardiovascular Risk in Hypertension – Can We Ask for More?

21 January 2018

1 reference

12 December 2020

Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension

1 reference

12 December 2020

Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group

1 reference

12 December 2020

Relation of Elevated Plasma Renin Activity at Baseline to Cardiac Events in Patients With Angiographically Proven Coronary Artery Disease

1 reference

12 December 2020

Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials

1 reference

12 December 2020

Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials

1 reference

12 December 2020

Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators

1 reference

12 December 2020

Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease

1 reference

12 December 2020

10.2165/11593540-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

25 August 2017

1000908976

0 references

1 reference